Clinical trial · Observational
Entia Liberty: Home Study
Entia Liberty: Home Study - Evaluation of Patient Preference for a Novel Full Blood Count Home Testing Device Versus Routine Venous Monitoring
NCT05462288CI-TRIAL-00074972completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Participants will be testing with the home monitoring device over the course of their treatment. They are to self-test on days where they are due to be going into hospital for their routine pre-treatment blood tests. Participants will be asked to fill in interim questionnaires and a final questionnaire to answer the study objectives.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Entia Liberty | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Patient Group
- interventionNames
- Device: Entia Liberty
Primary outcomes (1)
- measure
- To assess patient preference for the Liberty self-testing pathway as compared to standard of care.
- timeFrame
- 12 months
- description
- Patients will undergo the study procedures without change to their current pathway, at the end of the study, patients will compare the interventions via a SURVEY. The investigators will measure the success of the comparison by the % of patients who have chosen the investigators' product over the standard of care (4-5 rating out of 5).
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age ≥ 18 * Adequate English language skills (not requiring a translator) to participate in participant training and use the Liberty device * Patients willing and able to perform capillary blood self-testing at the same frequency as routine full blood count monitoring * Patients capable of providing informed consent before attending training * Patients able to attend a 1-hour virtual training session within 2 weeks of joining the study * Patients with a home Wi-Fi network or with adequate coverage at home via a 4G network * Patients with access to a laptop or smartphone to facilitate training * Patients with a diagnosis of ovarian or breast cancer * Patients whose HCPs can confirm are undergoing systemic anti-cancer treatments within two weeks of enrolment, with treatment expected to continue for at least two cycles Exclusion Criteria: * Patients with haematological malignancies * Patients with eyesight or hearing limitations or other disabilities that preclude the use of the Liberty device or participation in training unless they have a nominated caregiver who is capable of assisting with each test
References
Publications (0)
Data not yet available
No reference posted for this study.